Neurofibromatosis Type 1 (NF1) is a common neurological disorder caused by mutations in the gene encoding Neurofibromin, a p21Ras GTPase Activating Protein (GAP) [ We analyzed the effect of lovastatin treatment on p21Ras/MAPK by using Western blotting. nf1 +/− mice and wild-type littermate controls (wt) were injected with 10 mg/kg lovastatin subcutaneously once per day for 4 days, and they were sacrificed on the 4 th day, 6 hr after the final injection. Levels of p44/42 were examined in both cortex and hippocampus by SDS-PAGE. Proteins were transferred to membranes and hybridized with anti-phospho p44/42 MAPK (Cell Signaling) antibody. The results in Figure 1A show that the levels of phosphorylated p44/42 MAPK are higher in both the cortex Neurofibromin functions as a p21Ras GTPase-activating protein that catalyzes the conversion of active GTP bound p21Ras to the inactive GDP bound form. We therefore examined the impact of lovastatin treatment on p21Ras activity directly. Cortical and hippocampal extracts were reacted with GST-Raf1-RBD beads (Pierce Bio), which specifically bind p21Ras-GTP, the active form of p21Ras. p21Ras-GTP was resolved by SDS-PAGE and visualized with an anti-pan p21Ras antibody (Sigma). Again, p21Ras-GTP levels were elevated in the nf1 +/− compared to wt for both cortex (p < 0.05) and hippocampus (p < 0.05). Lovastatin treatment decreased the levels of p21Ras-GTP in both the cortex and hippocampus of nf1 +/− to the level of wt mice (cortex: p = 0.789, hippocampus: p = 0.195) ( Figure 1B ). This result is consistent with decreased levels of MAPK activity that we found in nf1 +/− mice. Altogether, these data demonstrate that lovastatin can decrease p21Ras/ MAPK activity in the cortex and hippocampus and may therefore be useful to treat cognitive deficits of the nf1 +/− mice. NF1 in humans is associated with a broad spectrum of cognitive profiles, which may include learning disabilities, attentional disorders, and altered visuospatial skills [2, 3, 21, 22]. We examined the effect of lovastatin on nf1 +/− mice in a variety of behavioral and cognitive tests to assess how the loss of NF1 impacted on these behaviors and whether lovastatin could rescue any observed deficits.
. Previous studies have shown that lovastatin can inhibit p21Ras isoprenylation and activity [8, 20] . Since the cognitive deficits caused by mutations in the NF1 gene may result from increased p21Ras activity, we hypothesized that lovastatin could rescue these deficits.
The NF1 null mutation mouse is lethal as a homozygote but is viable as a heterozygote [13] . Interestingly, we have not detected neuroanatomic deficits in the nf1 +/− mice, although they do display a range of behavioral abnormalities that parallel the cognitive profile associated with NF1 patients [1].
We analyzed the effect of lovastatin treatment on p21Ras/MAPK by using Western blotting. nf1 +/− mice and wild-type littermate controls (wt) were injected with 10 mg/kg lovastatin subcutaneously once per day for 4 days, and they were sacrificed on the 4 th day, 6 hr after the final injection. Levels of p44/42 were examined in both cortex and hippocampus by SDS-PAGE. Proteins were transferred to membranes and hybridized with anti-phospho p44/42 MAPK (Cell Signaling) antibody. The results in Figure 1A show that the levels of phosphorylated p44/42 MAPK are higher in both the cortex (p < 0.05) and hippocampus (p < 0.05) of nf1 +/− mice compared to wt. Several days of treatment with 10 mg/ kg of lovastatin decreased the levels of phosphorylated p44/42 MAPK in nf1 +/− mice, resulting in roughly equal amounts of phosphorylated p44/p42 MAPK as wt (cortex: p = 0.759, hippocampus: p = 0.850). Sample loading was controlled by reprobing the nitrocellulose membranes used for the analysis with an anti-p44/42 MAPK antibody.
Neurofibromin functions as a p21Ras GTPase-activating protein that catalyzes the conversion of active GTP bound p21Ras to the inactive GDP bound form. We therefore examined the impact of lovastatin treatment on p21Ras activity directly. Cortical and hippocampal extracts were reacted with GST-Raf1-RBD beads (Pierce Bio), which specifically bind p21Ras-GTP, the active form of p21Ras. p21Ras-GTP was resolved by SDS-PAGE and visualized with an anti-pan p21Ras antibody (Sigma). Again, p21Ras-GTP levels were elevated in the nf1 +/− compared to wt for both cortex (p < 0.05) and hippocampus (p < 0.05). Lovastatin treatment decreased the levels of p21Ras-GTP in both the cortex and hippocampus of nf1 +/− to the level of wt mice (cortex: p = 0.789, hippocampus: p = 0.195) ( Figure 1B ). This result is consistent with decreased levels of MAPK activity that we found in nf1 +/− mice. Altogether, these data demonstrate that lovastatin can decrease p21Ras/ MAPK activity in the cortex and hippocampus and may therefore be useful to treat cognitive deficits of the nf1 +/− mice. NF1 in humans is associated with a broad spectrum of cognitive profiles, which may include learning disabilities, attentional disorders, and altered visuospatial skills [2, 3, 21, 22]. We examined the effect of lovastatin on nf1 +/− mice in a variety of behavioral and cognitive tests to assess how the loss of NF1 impacted on these behaviors and whether lovastatin could rescue any observed deficits. Figure 2B ) and was significantly higher than nf1 +/− given placebo (PLSD, p < 0.05). These data demonstrate that nf1 +/− mice exhibit substantial attention deficits and that lovastatin treatment can reverse these deficits.
We have previously shown that nf1 +/− mice have abnormal spatial learning tested in the hidden version of the water maze [4, 23], a task that is sensitive to lesions of the hippocampus and multiple cortical sites including retrosplenial, orbitofrontal, medial prefrontal cortices, and the cingulum bundle [24] [25] [26] [27] . To test the hypothesis that lovastatin can rescue the deficits of nf1 +/− mice in this task, we injected 10 mg/kg lovastatin subcutaneously for 3 days before the first training day, and then 6 hr before behavioral training daily. Mice were trained with two trials per day. No differences were observed between genotypes and/or treatment groups in measures of acquisition, floating, thigmotaxic behavior, or swimming speed (data not shown).
Spatial learning was assessed in probe trials given at the end of water maze training on days 5 and 7, since previous studies have shown that probe trial performance is the most faithful measure of spatial learning in the Morris maze [28] . In the probe trials, the platform was removed from the pool and the mice were allowed to search for it for 60 s. Previous studies report a high incidence of attentiondeficit hyperactivity disorder (ADHD) in NF1 patients and support an association between ADHD and learning problems in these children [2, 29]. Children with ADHD are reported to have significantly reduced prepulse inhibition (PPI) [30] . PPI assays sensory "gating" of environmental stimuli. A sudden acoustic stimulus will normally elicit a whole-body startle response. If the startle-producing stimulus is preceded by a weak prestimulus, the startle response is inhibited in normal persons and animals [31] . We tested whether nf1 +/− mice have deficits in this task and whether these deficits could also be reversed by lovastatin treatment (as described above). A two-way repeated measures ANOVA revealed significant main effects of genotype els of PPI attribute the mechanism to a presynaptic inhibition of release [32] . Given that Ras activity is known to increase presynaptic release of transmitter [33] , the effects of lovastatin and PPI would work in concert to decrease presynaptic release. In the case of the nf1 +/− mutants, which have upregulated Ras function, the decrease merely brings them back into the normal range. In wt animals, release would be greatly curtailed, resulting in the enhancement of PPI.
We have previously shown that the learning deficits of the nf1 +/− mice are likely caused by impairments in LTP [4], a stable long-lasting change in synaptic strength widely believed to be a key cellular mechanism for learning and memory that is dependent upon Ras/MAPK function [5-7, 34]. We therefore determined whether the LTP deficits in nf1 +/− mice could be reversed by lovastatin. Mice were injected with 10 mg/kg of lovastatin as described above. We examined LTP in hippocampal slices at the Schaffer collateral/CA1 synapse, since LTP at this synapse has served as a model system for associative changes in synaptic strength between neurons [5-7]. LTP was measured after a 5 theta-burst stimulation protocol (TBS, five bursts 200 ms apart, each burst of 4 pulses at 100 Hz), which mimics in vivo activity of hippocampal neurons during exploratory behavior [35] . Figure 5 ). These data demonstrate that the lovastatin treatment completely reversed the LTP deficits of the nf1 +/− mice. The present results demonstrate that lovastatin treatment can reverse the biochemical, electrophysiological, and cognitive deficits observed in a mouse model of NF1 and that these deficits are not due to irreversible developmental changes. Previous studies have shown that an increase in p21Ras activity is central to the pathophysiology associated with NF1 [16] , and our biochemical data demonstrate that lovastatin reverses the abnormally elevated p21Ras/MAPK activity in an animal model of NF1. Importantly, our studies demonstrated that the dose of lovastatin that is effective in nf1 +/− mice did not affect cognitive function in control mice, a result consistent with randomized studies performed with human subjects that did not identify a reliable effect of lovastatin on cognitive function [36, 37] . Nevertheless, it is worth noting that there are sporadic reports that statins can be associated with mild cognitive impairment [38] . Altogether, the studies reported here demonstrate that the cognitive deficits associated with NF1 can be reversed by treatments with lovastatin, a widely prescribed drug that is known to be well tolerated even in long-term treatments. Thus, these data suggest that lovastatin could be used to treat the cognitive impairments associated with Neurofibromatosis Type 1 in humans.
Experimental Procedures

Animal Experiments
All animal protocols were approved by the Chancellor's Animal Research Committee at the University of California at Los Angeles, in accordance with the National Institutes of Health guidelines. Studies were performed in 129T2/SvEmsJ-C57BL/6 F1 hybrids generated by an F1 cross between nf1 +/− mice (maintained in the C57BL/6 background for more than 11 generations) and wild-type mice on the 129T2/SvEmsJ background with wild-type littermates used as controls. All experiments were carried out blind with respect to genotype and treatment. For p21Ras activity assay, p21Ras pull-down experiments were performed with the EZ-detect p21Ras activation kit (Pierce Biotechnology), according to the manufacturer's protocol. 25 l of sample per lane was loaded on SDS-PAGE. p21Ras-GTP was detected and quantified by Western blotting as described via an antipan-p21Ras antibody (Sigma). The ratio of Ras-GTP in each group was normalized to wt.
Lovastatin Solution and Pellet
Lateralized Reaction Time Task
Animals (placebo-treated: nf1 +/− = 14, wt = 10; lovastatin treated: nf1 +/− = 7, wt = 7) were food deprived to 90% of their free-feeding weights. Mice were trained in a miniaturized versions of a "5-choice" box (Med Associates, St Albans, VT). The chamber was equipped with a horizontal array of five apertures that could be internally illuminated and the opposite wall was fitted with a pellet magazine for reward delivery. Animals were shaped to produce a "poke and hold" response in the central aperture during which a side aperture would be illuminated. A correct response was scored when the animals correctly poked the aperture that had been illuminated. Animals that did not perform at 75% accuracy at 1 s target stimulus duration during the training phase were dropped. Mice were tested on a variable duration condition in which the target aperture was illuminated for 0.5, 1.0, or 2.0 s (varied within session). We measured correct responses/total trials, which vary as a function of the target stimulus duration and was therefore analyzed by use of stimulus duration as a repeated measure [40] .
Water Maze
The basic protocol for the water maze experiments has been previously described [11]. Mice from the 129T2/SvEmsJ-C57B/6 F1 genetic background were given two trials per day (30 s intertrial intervals) with a probe trial (60 s) at the end of training days 5 and 7. Mice were given subcutaneous injections of 10 mg/kg lovastatin or vehicle for 3 days before the first training day and then 6 hr before training every day.
Prepulse Inhibition
Mice were food deprived as described above. 5 min after placement in the conditioning chamber, mice were presented with 20 noise bursts (40 ms duration, 120 dB, <1 ms rise/fall time). In the prepulse inhibition phase, mice were presented with a total of 90 trials (30 trials each at 70, 75, and 80 dB). For each prepulse intensity (20 ms duration, <1 ms rise/fall time), there were three types of trial: prepulse alone, prepulse/startle stimulus, and startle stimulus alone. In the prepulse/startle stimulus trial, the onset of the prepulse preceded the onset of the startle stimulus by 100 ms. Background noise levels were maintained at 68 dB throughout testing, and the trials were spaced 15 s [41] .
Hippocampal LTP
Transverse hippocampal slices (400 mm thick) were placed in a submerged recording chamber perfused (2 ml/min) with ACSF containing 120 mM NaCl, 3.5 mM KCL, 2.5 mM CaCl 2 , 1.3 mM MgSO 4 , 1.25 mM NaH 2 PO 4 , 26 mM NaHCO 3 , and 10 mM D-glucose at 34°C. Field excitatory postsynaptic potentials (fEPSPs) were recorded with a Pt/Ir electrode (FHC, Bowdoinham, ME) from the stratum radiatum layer of the area CA1 elicited by stimulation of the Schaffer collateral/commissural afferents by two bipolar electrodes placed 300 m on either side of the recording electrode. Test pulses of 60 A alternated between the two electrodes every minute throughout the duration of the experiment. After 20 min of stable baseline, LTP was induced via a TBS protocol as described in the text delivered to the test pathway. Multiple slices from a single animal were averaged and entered into analysis as a single subject.
The responses from the last 10 min block of recordings (40-50 min) were compared for statistical tests.
Statistical Analysis
Western blots were analyzed with the one-sample t test (mean = 100, one tail upper). We analyzed percent time in training quadrant for the different genotypes from the water maze by using 2-way ANOVA. Attention data was analyzed with three-way repeatedmeasures ANOVA on the average of correct response rate. PPI data was analyzed with two-way repeated-measures ANOVA. For the electrophysiological experiments, the significance of differences between the groups was determined by two-way ANOVA. Post-hoc comparisons (Fisher's PLSD) between groups were carried out where appropriate.
